Expert Addresses Questions Surrounding Regorafenib and TAS-102 in mCRC TreatmentJanuary 6th 2017
Tanios Bekaii-Saab, MD, discusses questions regarding regorafenib and TAS-102 in mCRC, compares the mechanisms of action and toxicities of both therapies, and shares his views on the optimal sequencing of the 2 agents.
Clarity Still Needed on Cetuximab Benefit in mCRC, Expert SaysDecember 23rd 2016
Alan P. Venook, MD, discusses several of the big queries that remain in mCRC and the possible explanations for survival differences between left- and right-sided tumors. He also explained how answering these questions could pave the way for more novel treatment approaches.
Expert Addresses Need for Speedier Trial Design in Anaplastic Thyroid CancerNovember 22nd 2016
Immunotherapy has potential in anaplastic thyroid cancer, but it presents a challenge because of the length of time it takes to have an effect. Maria Cabanillas, MD, discusses an upcoming clinical trial that is combining immunotherapy with targeted therapy, that may offer a solution.
How Recent Study Findings Could Impact Biomarker Research in HER2+ Breast CancerNovember 8th 2016
New findings from a study suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer. Instead, gene networks— specifically those involving PI3 kinase —may provide a clearer picture of patient outcomes.
Immunotherapy Success Is Paving the Way for "Colder" Tumors, Allison SaysNovember 1st 2016
James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.
Pembrolizumab in HNSCC Only Scratches the Surface of Immunotherapy Potential, Expert SaysOctober 27th 2016
An expert discusses the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.
New CRC Treatment Options May Emerge From Mutation Discordance FindingsOctober 24th 2016
Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.
Tumor-Treating Fields Make Significant Impact in GBM and BeyondOctober 18th 2016
Optune, a noninvasive device that delivers tumor-treating fields to the brain, provides oncologists, specifically those who treat glioblastoma multiforme, an opportunity to apply technology as part of their standard treatment regimen.
Kumar Speaks on Role of MRD Testing in MyelomaOctober 10th 2016
<em>Targeted Oncology</em> speaks with Shaji Kumar, MD, to understand the roles that the new criteria for response and minimal residual disease (MRD) assessment in multiple myeloma and what role MRD testing will play going forward in multiple myeloma.<br />
Weber Speaks on Findings of Immunotherapy Study in MelanomaSeptember 2nd 2016
<div>Though Nivolumab (Opdivo) and ipilimumab (Yervoy) have demonstrated considerable success in the field of metastatic melanoma as both single agents and in combination, questions remain regarding sequencing the agents and the high toxicities that often occur when the 2 immunotherapies are used together.<br /> </div>
Expert Asserts Pembrolizumab to Play Important Role in Head and Neck Cancer TreatmentAugust 24th 2016
The FDA approval of pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma in August 2016 was extremely significant for this patient population, which previously had limited options following progression on a platinum-based chemotherapy.